Écrit par BONE THERAPEUTICS | 17 Avril 2013

First trial of its kind to investigate bone cell therapy in severe treatment-resistant osteoporosis

Gosselies, Belgium, 16 April 2013 - BONE THERAPEUTICS, the leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announces today that its partner, the Rheumatology Department of Erasme University Hospital (Brussels...

Écrit par WHO | 17 Avril 2013

16 April 2013 - As of 16 April 2013 (18:00 CET), the National Health and Family Planning Commission notified WHO of an additional three laboratory-confirmed cases of human infection with influenza A(H7N9) virus. Of the latest laboratory confirmed cases, one is from Jiangsu Province, one from Zhejiang Province, and one from Anhui Province.

The patients include:

a 60-year-old man from...

Écrit par DIA | 17 Avril 2013

BASEL, SWITZERLAND — 17th April, 2013 — Pharmaceutical professionals, regulatory agencies and academics will share knowledge and experience at DIA Europe’s conference on the Impact of the New Pharmacovigilance Legislation on Regulatory Affairs.


The event, to be held in London from 4th to 5th June, will highlight how changes in legislation will affect the way product assessment is...

Écrit par ANSM | 17 Avril 2013

L’association Réseau DES France lance une étude sur l’exposition in utero au diéthylstilbestrol ou DES (Distilbène, Stilboestrol Borne) et les effets indésirables qui peuvent en découler sur trois générations, en particulier le lien éventuel avec un risque accru de cancer du sein. Les résultats permettront de donner un éclairage complémentaire aux connaissances existantes...